| Abstract: |
Decades of randomized clinical trials have led to the development of a clear treatment approach for patients with limited-stage or extensive-stage small-cell lung cancer (SCLC). The standard first-line chemotherapy regimen is cisplatin or carboplatin plus etoposide, with the addition of radiation therapy for patients with limited-stage SCLC whose cancer is confined to the chest in a single tolerable radiation field. Patients with limited- And extensive-stage SCLC who demonstrate a response to first-line platinum-based therapy generally are offered prophylactic cranial irradiation (PCI), which has been shown to decrease the risk of intracranial recurrence and improve overall survival. ©2016 American Society of Clinical Oncology. |
